Tdspharm Co., Ltd. (KOSDAQ:464280)
South Korea · Delayed Price · Currency is KRW 9,830.00
+70.00 (0.72%)
Feb 5, 2026, 3:30 PM KST
Tdspharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 24,561 | 27,519 | 30,049 | 25,588 | 19,820 | 18,023 |
Other Revenue | -0 | -0 | - | -0 | -0 | 0 |
| 24,561 | 27,519 | 30,049 | 25,588 | 19,820 | 18,023 | |
Revenue Growth (YoY) | -20.27% | -8.42% | 17.43% | 29.11% | 9.97% | -6.19% |
Cost of Revenue | 18,110 | 19,818 | 22,140 | 19,454 | 15,864 | 14,802 |
Gross Profit | 6,451 | 7,701 | 7,910 | 6,134 | 3,956 | 3,220 |
Selling, General & Admin | 2,870 | 3,015 | 2,236 | 1,683 | 1,168 | 1,019 |
Research & Development | 702.07 | 622.5 | 441.2 | 478.84 | 356.11 | 437.28 |
Amortization of Goodwill & Intangibles | 74.24 | 66.44 | 16.49 | - | 0.62 | 0.62 |
Other Operating Expenses | 67.59 | 46.65 | 51.14 | 45.79 | 36.2 | 67.04 |
Operating Expenses | 4,002 | 3,972 | 2,893 | 2,353 | 1,641 | 1,599 |
Operating Income | 2,449 | 3,730 | 5,016 | 3,781 | 2,314 | 1,621 |
Interest Expense | -232.71 | -267.69 | -301.46 | -220.65 | -129.58 | -161.14 |
Interest & Investment Income | 973.2 | 846.66 | 521.07 | 216.96 | 53.02 | 51.31 |
Currency Exchange Gain (Loss) | -2.06 | -4.2 | -1.69 | -0.03 | 3.63 | -4.8 |
Other Non Operating Income (Expenses) | 23.9 | -4 | 254.57 | 115.14 | 165.98 | 127.03 |
EBT Excluding Unusual Items | 3,212 | 4,300 | 5,489 | 3,892 | 2,407 | 1,634 |
Gain (Loss) on Sale of Assets | 440.92 | -88.76 | 0.2 | 6.24 | 11.14 | - |
Asset Writedown | - | - | - | -52.24 | - | - |
Pretax Income | 3,653 | 4,212 | 5,489 | 3,846 | 2,419 | 1,634 |
Income Tax Expense | 371.34 | 493.87 | 801.14 | 390.36 | 355.75 | 282.3 |
Net Income | 3,281 | 3,718 | 4,688 | 3,456 | 2,063 | 1,351 |
Net Income to Common | 3,281 | 3,718 | 4,688 | 3,456 | 2,063 | 1,351 |
Net Income Growth | -29.63% | -20.70% | 35.66% | 67.52% | 52.66% | 35.28% |
Shares Outstanding (Basic) | 5 | 5 | 4 | 4 | 0 | 0 |
Shares Outstanding (Diluted) | 5 | 5 | 4 | 4 | 0 | 0 |
Shares Change (YoY) | 20.99% | 8.74% | -0.07% | 4511.34% | -7.60% | -0.00% |
EPS (Basic) | 620.38 | 802.99 | 1101.00 | 811.00 | 22325.01 | 13513.12 |
EPS (Diluted) | 620.38 | 802.99 | 1101.00 | 811.00 | 22325.01 | 13513.12 |
EPS Growth | -41.84% | -27.07% | 35.76% | -96.37% | 65.21% | 35.28% |
Free Cash Flow | 894.85 | 3,213 | 3,080 | 2,317 | 3,479 | 1,983 |
Free Cash Flow Per Share | 169.19 | 694.04 | 723.32 | 543.79 | 37650.19 | 19829.17 |
Gross Margin | 26.27% | 27.98% | 26.32% | 23.97% | 19.96% | 17.87% |
Operating Margin | 9.97% | 13.55% | 16.69% | 14.77% | 11.68% | 9.00% |
Profit Margin | 13.36% | 13.51% | 15.60% | 13.51% | 10.41% | 7.50% |
Free Cash Flow Margin | 3.64% | 11.68% | 10.25% | 9.05% | 17.55% | 11.00% |
EBITDA | 3,169 | 4,398 | 6,038 | 5,047 | 3,545 | 2,830 |
EBITDA Margin | 12.90% | 15.98% | 20.09% | 19.72% | 17.89% | 15.70% |
D&A For EBITDA | 720.06 | 668.59 | 1,022 | 1,266 | 1,230 | 1,208 |
EBIT | 2,449 | 3,730 | 5,016 | 3,781 | 2,314 | 1,621 |
EBIT Margin | 9.97% | 13.55% | 16.69% | 14.77% | 11.68% | 9.00% |
Effective Tax Rate | 10.17% | 11.73% | 14.59% | 10.15% | 14.71% | 17.28% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.